newsfilter
← Latest News
GlobeNewswire·

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 clinical trial of